• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F-FDG PET/MRI 在评估乳腺癌新辅助化疗病理完全缓解中的作用:系统评价和荟萃分析。

The role of F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.

机构信息

King's College Hospital, London, England.

Department of Radiology, Hilla University College, Babylon, Iraq.

出版信息

Radiat Oncol. 2024 Nov 19;19(1):164. doi: 10.1186/s13014-024-02507-5.

DOI:10.1186/s13014-024-02507-5
PMID:39563327
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11577720/
Abstract

BACKGROUND AND AIM

The present study aimed to evaluate the use of F-2-[F]-fluoro-2-deoxy-d-glucose (FDG) PET/MRI (Positron emission tomography-computed tomography) in predicting the pathological response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) compared to the use of MRI (Magnetic Resonance Imaging) alone.

METHODS

We searched numerous databases, including PubMed, Scopus, Embase, and Science Direct, using curated keywords. The variance of each study was determined using the binomial distribution, and STATA version 14 was used to analyze the data by performing random-effect models. Additionally, we calculated study heterogeneity using the chi-squared test and I index and utilized funnel plots and Egger tests to assess publication bias.

RESULTS

The current investigation analyzed 239 patients from six published studies. The pooled estimated sensitivity and specificity of F-FDG PET/MRI was 0.91 (95% CI = 0.90 to 0.92, I = 100% and P = 0.000) and 0.62 (95% CI = 0.53 to 0.72, I = 99.8% and P = 0.000), respectively. Pooled sensitivity and specificity of MRI were 0.78 (95%CI = 0.59 to 0.96, I = 100% and P = 0.000) and 0.56 (95%CI = 0.33 to 0.80, I = 99.8% and P = 0.000), respectively.

CONCLUSIONS

Based on our findings, the combined form of F-FDG PET/MRI imaging is more sensitive and specific than MRI alone for predicting response to NAC in BC patients.

摘要

背景与目的

本研究旨在评估 F-2-[F]-氟代-2-脱氧-D-葡萄糖(FDG)正电子发射断层扫描-计算机断层扫描(PET/CT)联合磁共振成像(MRI)在预测乳腺癌(BC)患者新辅助化疗(NAC)病理反应方面的应用,与单独使用 MRI 相比。

方法

我们使用已编制好的关键词在包括 PubMed、Scopus、Embase 和 Science Direct 在内的多个数据库中进行了搜索。使用二项式分布确定每个研究的方差,使用 STATA 版本 14 通过执行随机效应模型对数据进行分析。此外,我们使用卡方检验和 I 指数评估研究异质性,并使用漏斗图和 Egger 检验评估发表偏倚。

结果

本研究共分析了来自 6 项已发表研究的 239 名患者。FDG PET/MRI 的汇总估计敏感性和特异性为 0.91(95%置信区间 [CI] = 0.90 至 0.92,I = 100%,P = 0.000)和 0.62(95%CI = 0.53 至 0.72,I = 99.8%,P = 0.000)。MRI 的汇总敏感性和特异性分别为 0.78(95%CI = 0.59 至 0.96,I = 100%,P = 0.000)和 0.56(95%CI = 0.33 至 0.80,I = 99.8%,P = 0.000)。

结论

根据我们的发现,FDG PET/MRI 联合成像比单独使用 MRI 更敏感和特异,可用于预测 BC 患者对 NAC 的反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/58104345d86b/13014_2024_2507_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/0a2e8911590b/13014_2024_2507_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/cadae5594feb/13014_2024_2507_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/91ea377557fc/13014_2024_2507_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/58104345d86b/13014_2024_2507_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/0a2e8911590b/13014_2024_2507_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/cadae5594feb/13014_2024_2507_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/91ea377557fc/13014_2024_2507_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aae/11577720/58104345d86b/13014_2024_2507_Fig4_HTML.jpg

相似文献

1
The role of F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.F-FDG PET/MRI 在评估乳腺癌新辅助化疗病理完全缓解中的作用:系统评价和荟萃分析。
Radiat Oncol. 2024 Nov 19;19(1):164. doi: 10.1186/s13014-024-02507-5.
2
FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)与磁共振成像(MRI)用于评估乳腺癌患者新辅助化疗后的病理反应:诊断准确性研究的荟萃分析
Oncologist. 2016 Aug;21(8):931-9. doi: 10.1634/theoncologist.2015-0353. Epub 2016 Jul 8.
3
The accuracy of F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.F-FDG PET/CT 预测乳腺癌新辅助化疗病理反应的准确性:荟萃分析和系统评价。
Eur Radiol. 2017 Nov;27(11):4786-4796. doi: 10.1007/s00330-017-4831-y. Epub 2017 May 5.
4
The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.(18)F-FDG PET/CT与MRI在评估乳腺癌患者新辅助化疗后病理完全缓解中的作用:一项系统评价与Meta分析
Biomed Res Int. 2016;2016:3746232. doi: 10.1155/2016/3746232. Epub 2016 Feb 15.
5
Baseline [F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy.基线 [F]FDG PET/CT 和 MRI 一级乳腺癌肿瘤特征不能改善新辅助化疗的病理完全缓解预测。
Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3709-3718. doi: 10.1007/s00259-024-06815-6. Epub 2024 Jun 26.
6
Prognostic value of F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.18F-FDG PET 和 PET/CT 对评估乳腺癌新辅助化疗治疗反应的预后价值:系统评价和荟萃分析。
Breast Cancer Res. 2020 Oct 31;22(1):119. doi: 10.1186/s13058-020-01350-2.
7
Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.F18-氟脱氧葡萄糖正电子发射断层扫描/磁共振成像在乳腺癌中的分期/再分期性能:综述和荟萃分析。
Eur J Radiol. 2018 Oct;107:158-165. doi: 10.1016/j.ejrad.2018.09.003. Epub 2018 Sep 5.
8
The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.新辅助化疗前后F-18 FDG PET/CT扫描在乳腺癌中的价值:与MRI的比较
Acta Radiol. 2018 Jan;59(1):41-49. doi: 10.1177/0284185117705011. Epub 2017 Apr 21.
9
Baseline F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters.基线F-FDG PET/CT用于预测局部晚期乳腺癌患者新辅助化疗的病理反应及预后:肿瘤和淋巴器官代谢参数分析
Radiol Med. 2025 Mar;130(3):422-437. doi: 10.1007/s11547-025-01961-9. Epub 2025 Feb 12.
10
Subtype-Guided F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.基于亚型指导的 18F-FDG PET/CT 在新辅助化疗后腋窝淋巴结阳性乳腺癌患者中实施腋窝手术的可行性研究。
Oncologist. 2020 Apr;25(4):e626-e633. doi: 10.1634/theoncologist.2019-0583. Epub 2019 Dec 11.

引用本文的文献

1
Machine Learning-Driven radiomics on 18 F-FDG PET for glioma diagnosis: a systematic review and meta-analysis.基于18F-FDG PET的机器学习驱动的放射组学在胶质瘤诊断中的应用:一项系统评价和荟萃分析
Cancer Imaging. 2025 Aug 26;25(1):106. doi: 10.1186/s40644-025-00915-8.
2
Longitudinal MRI-Driven Multi-Modality Approach for Predicting Pathological Complete Response and B Cell Infiltration in Breast Cancer.基于纵向磁共振成像的多模态方法预测乳腺癌病理完全缓解及B细胞浸润
Adv Sci (Weinh). 2025 Mar;12(12):e2413702. doi: 10.1002/advs.202413702. Epub 2025 Feb 7.

本文引用的文献

1
Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer.专用乳腺[18F]FDG PET/MRI对乳腺癌新辅助化疗(靶向)治疗中原发性肿瘤和腋窝淋巴结反应的预测
Cancers (Basel). 2023 Jan 7;15(2):401. doi: 10.3390/cancers15020401.
2
Current and future burden of breast cancer: Global statistics for 2020 and 2040.乳腺癌的现状和未来负担:2020 年和 2040 年全球统计数据。
Breast. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.
3
Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid F-FDG PET/MRI in clinically node-positive breast cancer patients: a pilot study.
临床腋窝淋巴结阳性乳腺癌患者新辅助全身治疗后腋窝淋巴结对专用腋窝杂交 F-FDG PET/MRI 的反应:一项初步研究。
Clin Radiol. 2022 Oct;77(10):e732-e740. doi: 10.1016/j.crad.2022.06.010. Epub 2022 Jul 15.
4
Multiparametric F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.基于多参数F-FDG PET/MRI的影像组学预测乳腺癌新辅助化疗后的病理完全缓解
Cancers (Basel). 2022 Mar 29;14(7):1727. doi: 10.3390/cancers14071727.
5
Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy.PET/MRI预测新辅助化疗治疗的乳腺癌患者完全缓解的初步经验。
Mol Clin Oncol. 2022 Feb;16(2):50. doi: 10.3892/mco.2021.2483. Epub 2021 Dec 24.
6
Understanding breast cancer as a global health concern.理解乳腺癌作为一个全球健康问题。
Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14.
7
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.乳腺癌新辅助化疗后病理完全缓解的预测:专用乳腺 PET、全身 PET 和动态对比增强 MRI 的诊断性能比较。
Breast Cancer Res Treat. 2021 Jul;188(1):107-115. doi: 10.1007/s10549-021-06179-7. Epub 2021 Mar 17.
8
Multiparametric ultrasound examination for response assessment in breast cancer patients undergoing neoadjuvant therapy.多参数超声检查在乳腺癌新辅助治疗患者疗效评估中的应用。
Sci Rep. 2021 Jan 28;11(1):2501. doi: 10.1038/s41598-021-82141-3.
9
Prognostic value of F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.18F-FDG PET 和 PET/CT 对评估乳腺癌新辅助化疗治疗反应的预后价值:系统评价和荟萃分析。
Breast Cancer Res. 2020 Oct 31;22(1):119. doi: 10.1186/s13058-020-01350-2.
10
Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.使用超声散射系数监测乳腺癌患者新辅助化疗的反应:初步报告。
J Ultrason. 2019;19(77):89-97. doi: 10.15557/JoU.2019.0013. Epub 2019 Jun 28.